AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23834742 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over PMd
Number of subjects: 33
Study 23834742 — intervention group
Group type: COMPARATOR
Intervention: 5 Hz rTMS over PMd
Number of subjects: 33
Study 23834742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no rTMS)
Number of subjects: 33
Study 21501648 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental cigarettes with up to 60% glycerol containing tobacco-substitute sheet
Number of subjects: 0
Study 19070989 — intervention group
Group type: EXPERIMENTAL
Intervention: Anger mood induction
Number of subjects: 0
Study 19070989 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety mood induction
Number of subjects: 0
Study 19070989 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy mood induction
Number of subjects: 0
Study 19070989 — intervention group
Group type: COMPARATOR
Intervention: Neutral mood induction
Number of subjects: 0
Study 17692722 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 10 mg QD
Number of subjects: 508
Study 17692722 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg BID
Number of subjects: 508
Study 17692722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508
Study 17692722 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (valdecoxib, naproxen, placebo)
Number of subjects: 508
Study 15055856 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 373
Study 15055856 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg
Number of subjects: 373
Study 15055856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 373
Study 12515634 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC regimen (5‐Fu, epirubicin, cyclophosphamide)
Number of subjects: 48
Study 12515634 — intervention group
Group type: EXPERIMENTAL
Intervention: ET regimen (epirubicin, paclitaxel)
Number of subjects: 48
Study 9703125 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin
Number of subjects: 0
Study 7972346 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian extract (Valdispert forte, 405 mg t.i.d.)
Number of subjects: 14
Study 7972346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2789957 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting
Number of subjects: 27
Study 2789957 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines
Number of subjects: 27
Study 2789957 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study 1095248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol once a week (ER1)
Number of subjects: 575
Study 1095248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol daily for 2 months and then once a week (ER7ER1)
Number of subjects: 575
Study 1095248 — intervention group
Group type: COMPARATOR
Intervention: Ethionamide plus pyrazinamide plus cycloserine daily for 6 months and then ethionamide plus pyrazinamide daily (EtZC)
Number of subjects: 575
Study 1095248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol twice a week (ER2)
Number of subjects: 575
Study 1095248 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin plus ethambutol daily (ER7)
Number of subjects: 575
Study 31769402 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200 (1 × 10^9 CFU)
Number of subjects: 374
Study 31769402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study 31769402 — intervention group
Group type: EXPERIMENTAL
Intervention: PXVX0200
Number of subjects: 374
Study 30247329 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective sigmoidectomy
Number of subjects: 109
Study 30247329 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 109
Study 29045169 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical palmitoylethanolamide (PEA) (Defluxa)
Number of subjects: 15
Study 25483019 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater daily walking activity
Number of subjects: 92
Study 25483019 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity walking activity
Number of subjects: 92
Study 25483019 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daily walking activity
Number of subjects: 92
Study 25483019 — intervention group
Group type: COMPARATOR
Intervention: Control brain region (thalamus)
Number of subjects: 92
Study 23473435 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus device
Number of subjects: 54
Study 22074713 — intervention group
Group type: COMPARATOR
Intervention: clinical/CD4 monitoring
Number of subjects: 0
Study 22074713 — intervention group
Group type: EXPERIMENTAL
Intervention: clinical/CD4/viral load monitoring
Number of subjects: 0
Study 19420395 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-regulation group
Number of subjects: 113
Study 19420395 — intervention group
Group type: COMPARATOR
Intervention: Open group
Number of subjects: 113
Study 19420395 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 113
Study 17008337 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff sexuality training programme (two-day workshop)
Number of subjects: 74
Study 17008337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 74
Study 15286181 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit Information (EI) provided to participants with basal ganglia stroke
Number of subjects: 0
Study 15286181 — intervention group
Group type: COMPARATOR
Intervention: No Explicit Information (No-EI) for participants with basal ganglia stroke
Number of subjects: 0
Study 15286181 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit Information (EI) provided to healthy controls (HC)
Number of subjects: 0
Study 15286181 — intervention group
Group type: COMPARATOR
Intervention: No Explicit Information (No-EI) for healthy controls (HC)
Number of subjects: 0
Study 10612768 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime receipt 2 hours or more before incision
Number of subjects: 3028
Study 10612768 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus with a preoperative blood glucose level of 200 mg/dL or more
Number of subjects: 3028
Study 10612768 — intervention group
Group type: EXPERIMENTAL
Intervention: Staple use for skin closure
Number of subjects: 3028
Study 10612768 — intervention group
Group type: COMPARATOR
Intervention: Study period (January 1995‐March 1998)
Number of subjects: 3028
Study 9578541 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic drugs (AEDs)
Number of subjects: 0
Study 9578541 — intervention group
Group type: COMPARATOR
Intervention: Standard antiepileptic drugs (optimal doses)
Number of subjects: 0
Study 8111800 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (1.25 or 2.5 mg/day)
Number of subjects: 145
Study 8111800 — intervention group
Group type: COMPARATOR
Intervention: Glipizide (2.5 or 5 mg/day)
Number of subjects: 145
Study 8111800 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyburide (mean dose 8.5 mg/day)
Number of subjects: 145
Study 8111800 — intervention group
Group type: COMPARATOR
Intervention: Glipizide (mean dose 15.4 mg/day)
Number of subjects: 145
Study 8111800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both glyburide and glipizide
Number of subjects: 145
Study 3903062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisplatin, doxorubicin, cyclophosphamide: PACe)
Number of subjects: 85
Study 3903062 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil (CB)
Number of subjects: 85
Study 3903062 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (PACe)
Number of subjects: 85
Study 29343527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for NF1-OPG
Number of subjects: 155
Study 29343527 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy for sporadic OPG
Number of subjects: 155
Study 29343527 — intervention group
Group type: COMPARATOR
Intervention: Comparison between NF1-OPG and sporadic OPG
Number of subjects: 155
Study 29343527 — intervention group
Group type: EXPERIMENTAL
Intervention: VA improvement in NF1-OPG
Number of subjects: 155
Study 29343527 — intervention group
Group type: EXPERIMENTAL
Intervention: VA improvement in sporadic OPG
Number of subjects: 155
Study 27477797 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg methylprednisolone
Number of subjects: 40
Study 27477797 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 25435713 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice combined with physical practice for four weeks
Number of subjects: 20
Study 25435713 — intervention group
Group type: COMPARATOR
Intervention: Physical practice only
Number of subjects: 20
Study 20816708 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 39
Study 20816708 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 39
Study 16275178 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose atorvastatin (80 mg)
Number of subjects: 0
Study 16275178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose atorvastatin (10 mg)
Number of subjects: 0
Study 16275178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12523590 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-perfused catheter
Number of subjects: 12
Study 12523590 — intervention group
Group type: COMPARATOR
Intervention: Rectosphincteric balloon probe
Number of subjects: 12
Study 9665503 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 400 mg with delavirdine
Number of subjects: 14
Study 9665503 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir 600 mg with delavirdine
Number of subjects: 14
Study 9665503 — intervention group
Group type: COMPARATOR
Intervention: Indinavir 800 mg alone
Number of subjects: 14
Study 9665503 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with delavirdine
Number of subjects: 14
Study 7544368 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 treatment
Number of subjects: 0
Study 7544368 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 2547409 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered-dose inhaler (MDI)
Number of subjects: 7
Study 2547409 — intervention group
Group type: EXPERIMENTAL
Intervention: Pear shaped spacer attachment (PSS)
Number of subjects: 7
Study 912951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG) administered at five to eight week intervals.
Number of subjects: 28
Study 912951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no immunoglobulin).
Number of subjects: 28
Study 912951 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG).
Number of subjects: 28
Study 30225991 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A*02
Number of subjects: 641
Study 30225991 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B*35
Number of subjects: 641
Study 30225991 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01
Number of subjects: 641
Study 30225991 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DQB1*03:01
Number of subjects: 641
Study 30225991 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-A*01/B*08/DRB1*03:01
Number of subjects: 641
Study 27612943 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Health Program (9 sessions: 8 + 1 booster session)
Number of subjects: 166
Study 27612943 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study 25262270 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorapaxar
Number of subjects: 12944
Study 25262270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12944
Study 23543067 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min moderate (M) aerobic training
Number of subjects: 15
Study 23543067 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min moderate (M) aerobic training
Number of subjects: 15
Study 23543067 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-min heavy (H) aerobic training
Number of subjects: 15
Study 23543067 — intervention group
Group type: EXPERIMENTAL
Intervention: 60-min heavy (H) aerobic training
Number of subjects: 15
Study 19467804 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive teaching session focused on prostate and rectum MR anatomy compared with CT anatomy.
Number of subjects: 31
Study 19467804 — intervention group
Group type: COMPARATOR
Intervention: 3D‐CRT planning without mention of prostate or rectal contouring.
Number of subjects: 31
Study 19022811 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose immunosuppressive therapy and autologous stem cell transplantation
Number of subjects: 0
Study 19022811 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0
Study 16855072 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 200 mg bid
Number of subjects: 32
Study 16855072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 12500203 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 25 mg twice daily
Number of subjects: 44
Study 12500203 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 125 mg twice daily
Number of subjects: 44
Study 12500203 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA-985 250 mg twice daily
Number of subjects: 44
Study 12500203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 10663216 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight
Number of subjects: 1268
Study 8792942 — intervention group
Group type: EXPERIMENTAL
Intervention: cloxacillin
Number of subjects: 20
Study 8792942 — intervention group
Group type: EXPERIMENTAL
Intervention: cephalexin
Number of subjects: 20
Study 8792942 — intervention group
Group type: EXPERIMENTAL
Intervention: erythromycin
Number of subjects: 20
Study 8792942 — intervention group
Group type: EXPERIMENTAL
Intervention: fusidic acid
Number of subjects: 20
Study 1297231 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutathione (GSH, 1200 mg, i.v.)
Number of subjects: 0
Study 1297231 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 0
Study 6394127 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin-ticarcillin (NT)
Number of subjects: 60
Study 6394127 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin-ticarcillin (TT)
Number of subjects: 60
Study 31080947 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-flow anaesthesia (MF)
Number of subjects: 80
Study 31080947 — intervention group
Group type: COMPARATOR
Intervention: High-flow anaesthesia (HF)
Number of subjects: 80
Study 31080947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MF and HF anaesthesia
Number of subjects: 80
Study 29025005 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release paracetamol (ER-APAP) 2 x 665 mg
Number of subjects: 25
Study 29025005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 29025005 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study 29025005 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-APAP
Number of subjects: 25
Study 27048210 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine (20 or 40 mg) with or without ethanol
Number of subjects: 100
Study 27048210 — intervention group
Group type: COMPARATOR
Intervention: Vortioxetine (10 mg/day)
Number of subjects: 100
Study 27048210 — intervention group
Group type: COMPARATOR
Intervention: Ethanol
Number of subjects: 100
Study 25293834 — intervention group
Group type: EXPERIMENTAL
Intervention: Haptotherapy treatment
Number of subjects: 3
Study 25293834 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet psycho-education
Number of subjects: 3
Study 25293834 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 3
Study 22516039 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dosing regimen (15 mg MTX once a week)
Number of subjects: 19
Study 22516039 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated dosing regimen (25 mg MTX once a week)
Number of subjects: 19
Study 19853680 — intervention group
Group type: EXPERIMENTAL
Intervention: RUTI (5-200 microg doses)
Number of subjects: 6
Study 19853680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17963623 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase (r‐Sak)
Number of subjects: 210
Study 17963623 — intervention group
Group type: COMPARATOR
Intervention: Recombinant tissue-type plasminogen activator (rt‐PA)
Number of subjects: 210
Study 16116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine sedation (0.5 mg . kg(‐1) . h(‐1) continuous infusion after IV administration of 0.01 mg/kg midazolam)
Number of subjects: 30
Study 16116012 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (volume-equivalent)
Number of subjects: 30
Study 16116012 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine sedation
Number of subjects: 30
Study 12324731 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Vital Capacity Maneuvers (TVCM)
Number of subjects: 24
Study 12324731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no total vital capacity maneuver)
Number of subjects: 24
Study 12324731 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 24
Study 10408158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy for 2 weeks before LH-RH analogue injection
Number of subjects: 25
Study 10408158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone acetate (CMA) therapy for 4 weeks before LH-RH analogue injection
Number of subjects: 25
Study 10408158 — intervention group
Group type: COMPARATOR
Intervention: LH-RH analogue injection
Number of subjects: 25
Study 10408158 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA administration after LH-RH analogue application
Number of subjects: 25
Study 7673760 — intervention group
Group type: EXPERIMENTAL
Intervention: Thallium-201 SPECT
Number of subjects: 170
Study 7673760 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise test (ST-depression)
Number of subjects: 170
Study 7673760 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SPECT score >= 4 and/or ST-depression in >= 3 leads
Number of subjects: 170
Study 2405132 — intervention group
Group type: EXPERIMENTAL
Intervention: Data coordination and management by the DDC of the GFRD Study
Number of subjects: 0
Study 2405132 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination and communication tasks in the multicenter study
Number of subjects: 0
Study 6109465 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam (0.4‐0.8 mg)
Number of subjects: 30
Study 6109465 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoctamine (10‐20 mg)
Number of subjects: 30
Study 6109465 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 31849062 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial pesticide (26.7% boscalid + 6.7% pyraclostrobin) at varying concentrations
Number of subjects: 480
Study 31849062 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration model for boscalid
Number of subjects: 480
Study 31849062 — intervention group
Group type: EXPERIMENTAL
Intervention: Calibration model for pyraclostrobin
Number of subjects: 480
Study 30611215 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral position
Number of subjects: 54
Study 30611215 — intervention group
Group type: COMPARATOR
Intervention: Sniffing position
Number of subjects: 54
Study 28157491 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg dexamethasone
Number of subjects: 24
Study 28157491 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg dexamethasone
Number of subjects: 24
Study 28157491 — intervention group
Group type: COMPARATOR
Intervention: 0 mg dexamethasone (control)
Number of subjects: 24
Study 28157491 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg and 8 mg dexamethasone
Number of subjects: 24
Study 26439756 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program with regular home visits commencing antenatally and a parenting course starting at 2 years
Number of subjects: 233
Study 26439756 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention program
Number of subjects: 233
Study 26439756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 233
Study 23332349 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel followed by capecitabine (D → C)
Number of subjects: 51
Study 23332349 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel administered concomitantly with capecitabine (DC)
Number of subjects: 51
Study 23332349 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with triple-negative breast cancer
Number of subjects: 51
Study 21085036 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training for 16 weeks
Number of subjects: 319
Study 21085036 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 319
Study 19471901 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapeutic interventions and coping skills training (QE)
Number of subjects: 117
Study 19471901 — intervention group
Group type: COMPARATOR
Intervention: Conventional detoxification treatment (KE)
Number of subjects: 117
Study 16881464 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific-exercise-training group (Pilates-based therapeutic exercise)
Number of subjects: 39
Study 16881464 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 39
Study 15005830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial subcutaneous injections of rGLP-1 (76 nmol 30 min before meals, four times daily)
Number of subjects: 19
Study 15005830 — intervention group
Group type: EXPERIMENTAL
Intervention: Prandial subcutaneous injections of rGLP-1
Number of subjects: 19
Study 15005830 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of rGLP-1 (12.7 nmol/h)
Number of subjects: 19
Study 15005830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 11352777 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoglycaemia and caffeine
Number of subjects: 16